ArticleAnnals of the rheumatic diseases2017
Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases.
Article in Annals of the rheumatic diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Guideline
- The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026Review
- Therapeutic advances in multiple sclerosis: Novel therapies (immune checkpoint inhibitors, CAR-T, Anti-CD40L).Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Tislelizumab-induced hemophagocytic lymphohistiocytosis in a patient with microsatellite instability-high colon cancer and coexisting systemic lupus erythematosus: a case report and literature review.Frontiers in oncology · 2025Article
- Fertility Preservation in the Era of Immuno-Oncology: Lights and Shadows.Journal of personalized medicine · 2024Review
- Calprotectin in Patients with Rheumatic Immunomediated Adverse Effects Induced by Checkpoints Inhibitors.Cancers · 2023Article
- From the Catastrophic Objective Irreproducibility of Cancer Research and Unavoidable Failures of Molecular Targeted Therapies to the Sparkling Hope of Supramolecular Targeted Strategies.International journal of molecular sciences · 2023Review
- Article
- Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience.Frontiers in oncology · 2023Article
- Imaging Findings in Patients with Immune Checkpoint Inhibitor-Induced Arthritis.Diagnostics (Basel, Switzerland) · 2022Article
- Immunotherapy-induced retinopathy mimicking cancer associated retinopathy.American journal of ophthalmology case reports · 2022Article
- Article
- Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.Journal of cancer research and clinical oncology · 2021Article
- Step-by-Step Immune Activation for Suicide Gene Therapy Reinforcement.International journal of molecular sciences · 2021Review
- Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors.Scientific reports · 2021Observational
- Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy.eNeurologicalSci · 2021Article
- The Potential Regulatory Roles of Circular RNAs in Tumor Immunology and Immunotherapy.Frontiers in immunology · 2020Review
- Nivolumab-Induced Recurrence of Rheumatoid Arthritis in a Patient with Metastatic Gastric Adenocarcinoma.Clinical drug investigation · 2019Article
- Immunometabolism: A new target for improving cancer immunotherapy.Advances in cancer research · 2019Review
- Rheumatic immune-related adverse events from cancer immunotherapy.Nature reviews. Rheumatology · 2018Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
27566797What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.